glp 1 with cv benefit GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Comprehensive Overview of GLP-1 RAs
Description
These data suggest that although these receptors are important for regulating normal body mass, they are not unique to RYGB
Sudden decrease in urine output
doi: 10.2337/db13-0954
The recent positive topline results from Eli Lilly and Company 's ATTAIN-MAINTAIN trial for orforglipron, however, signal a potential paradigm shift
Treatment continuation depends on achieving specified weight loss targets
Some patients report appetite changes within the first few days of this dose
